Currently Enrolling Study
Acucela SEATTLE Study for Advanced Dry Age-Related Macular Degeneration (AMD)
Purpose of study:
This research study is being done to see how safe and effective a drug called emixustat is in treating geographic atrophy due to the dry form of age-related macular degeneration. We want to find out whether emixustat prevents geographic atrophy from getting worse over time.
What is Geographic Atrophy (GA)?
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for "straight-ahead" activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. The macula is located in the center of the retina, the light-sensitive tissue at the back of the eye. Geographic atrophy is an advanced form of dry macular degeneration. Currently, there is no treatment available to prevent vision loss once GA has developed.
What is involved?
Research participants will make 13 visits to the Eye Institute over the course of 2 years, where testing will be performed for the study. About 75% of the people who participate in this study will be randomly assigned to receive a dose of emixustat and about 25% of participants will receive a placebo (a pill that contains no active drug). Participants will not be told which group they have been assigned to.
Research volunteers will receive $50 for each study visit that they complete. Reimbursement is available for mileage to and from study appointments. Taxi service to and from research appointments is also available.
Additional information about the SEATTLE study can be found at ClinicalTrials.gov.
IRB Approval: PRO00019439, 5/8/2013